AtriCure (NASDAQ:ATRC) Stock Price Expected to Rise, Piper Sandler Analyst Says

AtriCure (NASDAQ:ATRC - Free Report) had its price target boosted by Piper Sandler from $40.00 to $50.00 in a research note released on Thursday,Benzinga reports. Piper Sandler currently has an overweight rating on the medical device company's stock.

Other equities research analysts have also recently issued research reports about the stock. UBS Group lifted their price target on shares of AtriCure from $35.00 to $40.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. JMP Securities reissued a "market outperform" rating and set a $60.00 target price on shares of AtriCure in a research note on Monday, February 10th. Oppenheimer lifted their price objective on AtriCure from $32.00 to $36.00 and gave the stock an "outperform" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. raised their target price on AtriCure from $40.00 to $51.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Finally, Stifel Nicolaus boosted their price target on AtriCure from $36.00 to $48.00 and gave the stock a "buy" rating in a research report on Thursday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $51.56.

AtriCure Price Performance

Shares of AtriCure stock traded up $1.35 on Thursday, hitting $40.94. The company's stock had a trading volume of 577,628 shares, compared to its average volume of 590,066. The company has a market capitalization of $2.00 billion, a price-to-earnings ratio of -49.33 and a beta of 1.46. AtriCure has a 1 year low of $18.94 and a 1 year high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.59 and a current ratio of 3.62. The firm has a fifty day moving average price of $35.76 and a 200-day moving average price of $31.50.

Institutional Trading of AtriCure

Hedge funds and other institutional investors have recently made changes to their positions in the company. Arcadia Investment Management Corp MI acquired a new stake in AtriCure during the third quarter worth $28,000. Johnson Financial Group Inc. raised its holdings in AtriCure by 1,184.1% in the 4th quarter. Johnson Financial Group Inc. now owns 1,618 shares of the medical device company's stock valued at $49,000 after buying an additional 1,492 shares during the period. Heck Capital Advisors LLC acquired a new position in AtriCure in the fourth quarter valued at about $60,000. Venturi Wealth Management LLC boosted its stake in AtriCure by 1,337.6% during the fourth quarter. Venturi Wealth Management LLC now owns 2,257 shares of the medical device company's stock worth $69,000 after buying an additional 2,100 shares during the period. Finally, KBC Group NV lifted its stake in AtriCure by 65.3% during the fourth quarter. KBC Group NV now owns 2,360 shares of the medical device company's stock worth $72,000 after purchasing an additional 932 shares in the last quarter. Institutional investors and hedge funds own 99.11% of the company's stock.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.